Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines ...
New Year's Day commemorates the passing of time and the start of a new chapter, so it is fitting that the same day also presents an opportunity to breathe new life into thousands of creative works ...
Typing a web address directly into your browser feels harmless. In fact, it feels normal. But new research shows that a simple habit is now one of the riskiest things you can do online. A recent study ...
Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...
An Arizona man looking for a huge payday for his ‘Lambo.com’ domain wound up left with nothing but legal fees and a loss of his initial investment, after a United States district court ruled in favor ...
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, ...
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly ...
The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback